☆ 4.7 Letter

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Volume 139, Issue 3, Pages 1035-1037

Publisher

MOSBY-ELSEVIER

DOI: 10.1016/j.jaci.2016.09.014

Keywords

Funding

Pfizer
TEVA
Blogen Idec
Novartis
Bayer Schering Pharma
GlaxoSmithKline
Merck-Serono
AbbVie
UCB
Genmab
Reneneron
Biogen-Idec
Roche

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Publisher

MOSBY-ELSEVIER

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Publisher

MOSBY-ELSEVIER

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper